a08632 boster mad2 antibody  (Boster Bio)

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Pan-Cancer Analysis of SGO2 Expression ( A ) SGO2 expression profiles across pan-cancers were analyzed using data from the TCGA database. Tumor samples (represented as red boxes) were compared against normal samples (represented as blue boxes) via the Mann-Whitney U test to assess expression differences. ( B ) SGO2 expression patterns across pan-cancers were interrogated utilizing the GEPIA web platform. Tumor samples (depicted as red dots) were contrasted with normal samples (depicted as green dots), with statistical testing following GEPIA’s default analytical pipeline (*p < 0.05, **p < 0.01,***p < 0.001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, MANN-WHITNEY

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Investigation of SGO2 Expression in LUAD. ( A ) Paired comparison: SGO2 expression in tumor vs. matched adjacent normal tissues from LUAD patients (paired t-test). ( B ) Unpaired comparison: SGO2 expression in tumor vs. normal tissues (unpaired t-test). ( C ) Immunohistochemical validation: Immunohistochemical analysis assessed SGO2 expression in LUAD tumor tissues and adjacent peri-tumor tissues from 21 patients (n = 21). Comparison of relative SGO2 expression levels (top) and positive staining area percentages (bottom) between tumor and peri-tumor tissues used paired t-test. ( D ) Clinical stage-related analysis: Based on the TCGA database, SGO2 expression was analyzed across subgroups of T stage, N stage, M stage, and pathological stage. Statistical method: One-way ANOVA with Bonferroni post-hoc test. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, Comparison, Immunohistochemical staining, Biomarker Discovery, Staining

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Elevated SGO2 expression was associated with poor prognosis in LUAD patients. ( A-C ) Kaplan-Meier survival analyses (via log-rank test) from TCGA database comparing LUAD patients with high vs. low SGO2 expression (stratified by median). ( A ) OS: High-expression group (n = 265) showed significantly worse prognosis than low-expression group (n = 265) (HR = 1.64, p < 0.001). ( B ) DSS: High-expression group (n = 247) had poorer outcomes than low-expression group (n = 248) (HR = 1.87, p < 0.001). ( C ) PFS: High-expression group (n = 265) exhibited shorter PFS than low-expression group (n = 265) (HR = 1.47, p = 0.005). ( D-E ) Validation in GEO datasets (log-rank test): ( D ) GSE13213 : High-expression group (n = 75) had significantly reduced survival vs. low-expression group (n = 42) (p < 0.01). ( E ) GSE31210 : High-expression group (n=84) showed worse prognosis compared to low-expression group (n = 120) (p = 0.005). HR: Hazard ratio.

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, Biomarker Discovery

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: The diagnostic ROC curve for SGO2. ( A ) Receiver operating characteristic (ROC) curve evaluating SGO2 expression as a diagnostic biomarker for LUAD. The area under the curve (AUC) was 0.873 (95% CI: 0.843-0.903), indicating high discriminatory power.

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Diagnostic Assay, Expressing, Biomarker Discovery

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: SGO2 expression in LUAD cell lines relative to normal Beas-2B cells. ( A ) Combined subpanels showing relative SGO2 mRNA expression: ( a-c ) Relative SGO2 mRNA expression in A549 ( a ), H1975( b ) and H1299 ( c ) cells, normalized to Beas-2B. (n = 3, Student’s t-test). ( B-C ) Representative western blot ( B ) and quantitative analysis ( C ) of SGO2 protein expression in the same cell lines. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} -actin served as the loading control (n = 3, one-way ANOVA with Tukey’s post hoc test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, Western Blot, Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: SGO2 knockdown suppressed malignant behaviors in LUAD cells. ( A-B ) Validation of siRNA-mediated SGO2 knockdown efficiency by ( A ) qPCR and ( B ) Western blot. (n = 3, one-way ANOVA with Tukey’s post hoc test). ( C-E ) Proliferation (CCK-8), migration (wound healing), and invasion (Matrigel) assays in SGO2-depleted H1299 cells. (n = 3, Student’s t-test). ( F ) Western blot analysis of EMT markers (N-cadherin, E-cadherin, Vimentin) in SGO2-knockdown H1299 cells with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} -actin served as loading control. (n = 3, Student’s t-test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Knockdown, Biomarker Discovery, Western Blot, CCK-8 Assay, Migration, Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Knockdown of SGO2 affected the cell cycle in LUAD cells. ( A ) Flow cytometry analysis of cell cycle distribution (G1, S, G2/M phases) in si-SGO2 and si-NC groups. (n = 3, two-way ANOVA with Sidak’s test). ( B ) Western blot of cell cycle proteins (Cyclin B1, Cyclin D1). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} -actin served as control (n = 3, Student’s t-test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Knockdown, Flow Cytometry, Western Blot, Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: SGO2 regulated LUAD cell migration and invasion via MAD2. ( A ) GO and KEGG enrichment analysis of genes associated with SGO2. (The use permission from Kanehisa Laboratories has been obtained.) ( B ) Correlation analysis between SGO2 and MAD2 expression (Pearson’s R = 0.62, p < 0.001). ( C-D ) Verification of SGO2 overexpression efficiency using qPCR and Western blot, and analysis of MAD2 expression following SGO2 knockdown or overexpression (n = 3, Student’s t-test). ( E ) Invasion and migration assays of H1299 cells in three groups: SGO2 overexpression (OE-SGO2), control (OE-SGO2-NC), and SGO2-OE with MAD2 inhibitor (OE-M2I-1) (n = 3, one-way ANOVA with Tukey’s post hoc test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Migration, Expressing, Over Expression, Western Blot, Knockdown, Control

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 increases the risk of poor prognosis for LUAD. (A, E, and H) Based on the TCGA database, SGO2 expression, ROC curve, and survival analysis in LUAD. (B, F, and I) Based on the GEO database, the validation dataset GSE30219 was used to verify the SGO2 expression, ROC curve, and survival analysis in LUAD. (C) The expression of SGO2 in LUAD and normal tissue. (D) The protein expression of SGO2 in LUAD and normal tissue. (G and J) Immunohistochemical staining of SGO2 in LUAD and normal tissue.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing, Biomarker Discovery, Immunohistochemical staining, Staining

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: High SGO2 is associated with a higher TNM stage of LUAD. (A) Based on the TCGA and GSE30219, the expression of SGO2 in T1 vs T2. (B) Based on the TCGA and GSE30219, the expression of SGO2 in N0 vs N1. (C) Based on the TCGA and GSE31210, the expression of SGO2 in stage I vs stage II + III. (D and G) Based on IHC, the protein expression and staining of SGO2 in T1 vs T2. (E and H) Based on IHC, the protein expression and staining of SGO2 in N0 vs N1. (F and I) Based on IHC, the protein expression and staining of SGO2 in stage I vs stage II + III.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing, Staining

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 silencing inhibits the proliferation of lung cancer cells. (A)SGO2 expression after knockdown in A549 and H1299. (B)CCK8 assays were performed to detect A549 and H1299 proliferation. (C)Edu assays were performed to detect A549 and H1299 proliferation.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing, Knockdown

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: The downregulation of SGO2 affects migration, invasion, and EMT. (A) A Transwell assay was performed to examine the effect of SGO2 knockdown on A549 and H1299 cells. (C) A wound healing assay was performed to examine the effect of SGO2 knockdown on A549 and H1299 cells. (B and D) WB assay the expression levels of E-cadherin, N-cadherin, Vimentin, and Cytokeratin in A549 and H1299 to evaluate the effect on EMT after SGO2 knockdown.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Migration, Transwell Assay, Knockdown, Wound Healing Assay, Expressing

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 expression and tumor immune infiltration. (A) the expression of SGO2 was positively correlated with the infiltration of Memory B cells, Activated CD4+ memory T cells, and CD8+ T cells, while the infiltration of Memory B cells and Tregs decreased with increasing SGO2 expression. (B) Correlation of SGO2 expression with 28 distinct types of tumor-infiltrating immune cells based on ssGSEA.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: High SGO2 has multiple therapeutic benefits. (A) Comparison of mutational landscapes of SGO between high cluster and low cluster, and Comparison of tumor mutation burden (TMB) between two clusters. (B) Comparison of first-line chemotherapy and targeted therapy drug targets of high and low SGO2 clusters. (C) Comparison of immunomodulatory drug targets of high and low SGO2 clusters.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Comparison, Mutagenesis

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 increases the risk of poor prognosis for LUAD. (A, E, and H) Based on the TCGA database, SGO2 expression, ROC curve, and survival analysis in LUAD. (B, F, and I) Based on the GEO database, the validation dataset GSE30219 was used to verify the SGO2 expression, ROC curve, and survival analysis in LUAD. (C) The expression of SGO2 in LUAD and normal tissue. (D) The protein expression of SGO2 in LUAD and normal tissue. (G and J) Immunohistochemical staining of SGO2 in LUAD and normal tissue.

Article Snippet: The following primary antibodies were used: E-Cadherin (Cat. # 20874-1-AP; 1:20000; Proteintech, Wuhan, China), N-Cadherin (Cat. # 22018-1-AP; 1:2000; Proteintech), Vimentin (Cat. # abs171412; 1:1000; absin, Shanghai, China), Pan-Cytokeratin (Cat. # BH0149; 1:1000; Bioss, Beijing, China), and SGO2 (Cat. # A30763-1; 1:1000; Boster, Wuhan, China).

Techniques: Expressing, Biomarker Discovery, Immunohistochemical staining, Staining

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: High SGO2 is associated with a higher TNM stage of LUAD. (A) Based on the TCGA and GSE30219, the expression of SGO2 in T1 vs T2. (B) Based on the TCGA and GSE30219, the expression of SGO2 in N0 vs N1. (C) Based on the TCGA and GSE31210, the expression of SGO2 in stage I vs stage II + III. (D and G) Based on IHC, the protein expression and staining of SGO2 in T1 vs T2. (E and H) Based on IHC, the protein expression and staining of SGO2 in N0 vs N1. (F and I) Based on IHC, the protein expression and staining of SGO2 in stage I vs stage II + III.

Article Snippet: The following primary antibodies were used: E-Cadherin (Cat. # 20874-1-AP; 1:20000; Proteintech, Wuhan, China), N-Cadherin (Cat. # 22018-1-AP; 1:2000; Proteintech), Vimentin (Cat. # abs171412; 1:1000; absin, Shanghai, China), Pan-Cytokeratin (Cat. # BH0149; 1:1000; Bioss, Beijing, China), and SGO2 (Cat. # A30763-1; 1:1000; Boster, Wuhan, China).

Techniques: Expressing, Staining

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 silencing inhibits the proliferation of lung cancer cells. (A)SGO2 expression after knockdown in A549 and H1299. (B)CCK8 assays were performed to detect A549 and H1299 proliferation. (C)Edu assays were performed to detect A549 and H1299 proliferation.

Article Snippet: The following primary antibodies were used: E-Cadherin (Cat. # 20874-1-AP; 1:20000; Proteintech, Wuhan, China), N-Cadherin (Cat. # 22018-1-AP; 1:2000; Proteintech), Vimentin (Cat. # abs171412; 1:1000; absin, Shanghai, China), Pan-Cytokeratin (Cat. # BH0149; 1:1000; Bioss, Beijing, China), and SGO2 (Cat. # A30763-1; 1:1000; Boster, Wuhan, China).

Techniques: Expressing, Knockdown

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: The downregulation of SGO2 affects migration, invasion, and EMT. (A) A Transwell assay was performed to examine the effect of SGO2 knockdown on A549 and H1299 cells. (C) A wound healing assay was performed to examine the effect of SGO2 knockdown on A549 and H1299 cells. (B and D) WB assay the expression levels of E-cadherin, N-cadherin, Vimentin, and Cytokeratin in A549 and H1299 to evaluate the effect on EMT after SGO2 knockdown.

Article Snippet: The following primary antibodies were used: E-Cadherin (Cat. # 20874-1-AP; 1:20000; Proteintech, Wuhan, China), N-Cadherin (Cat. # 22018-1-AP; 1:2000; Proteintech), Vimentin (Cat. # abs171412; 1:1000; absin, Shanghai, China), Pan-Cytokeratin (Cat. # BH0149; 1:1000; Bioss, Beijing, China), and SGO2 (Cat. # A30763-1; 1:1000; Boster, Wuhan, China).

Techniques: Migration, Transwell Assay, Knockdown, Wound Healing Assay, Expressing

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 expression and tumor immune infiltration. (A) the expression of SGO2 was positively correlated with the infiltration of Memory B cells, Activated CD4+ memory T cells, and CD8+ T cells, while the infiltration of Memory B cells and Tregs decreased with increasing SGO2 expression. (B) Correlation of SGO2 expression with 28 distinct types of tumor-infiltrating immune cells based on ssGSEA.

Article Snippet: The following primary antibodies were used: E-Cadherin (Cat. # 20874-1-AP; 1:20000; Proteintech, Wuhan, China), N-Cadherin (Cat. # 22018-1-AP; 1:2000; Proteintech), Vimentin (Cat. # abs171412; 1:1000; absin, Shanghai, China), Pan-Cytokeratin (Cat. # BH0149; 1:1000; Bioss, Beijing, China), and SGO2 (Cat. # A30763-1; 1:1000; Boster, Wuhan, China).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: High SGO2 has multiple therapeutic benefits. (A) Comparison of mutational landscapes of SGO between high cluster and low cluster, and Comparison of tumor mutation burden (TMB) between two clusters. (B) Comparison of first-line chemotherapy and targeted therapy drug targets of high and low SGO2 clusters. (C) Comparison of immunomodulatory drug targets of high and low SGO2 clusters.

Article Snippet: The following primary antibodies were used: E-Cadherin (Cat. # 20874-1-AP; 1:20000; Proteintech, Wuhan, China), N-Cadherin (Cat. # 22018-1-AP; 1:2000; Proteintech), Vimentin (Cat. # abs171412; 1:1000; absin, Shanghai, China), Pan-Cytokeratin (Cat. # BH0149; 1:1000; Bioss, Beijing, China), and SGO2 (Cat. # A30763-1; 1:1000; Boster, Wuhan, China).

Techniques: Comparison, Mutagenesis